OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

OSE Immunotherapeutics SA announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase I clinical trial for CoVepiT, the company’s investigational prophylactic COVID-19 vaccine candidate.